The Food and Drug Administration yesterday announced a firmware update to reduce the risk of rapid battery depletion and address cybersecurity vulnerabilities in certain Abbott devices that provide pacing for slow heart rhythms and electrical shock or pacing to stop dangerously fast heart rhythms. The update applies to several families of Abbott (formerly St. Jude Medical) implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators, including certain devices included in a 2016 recall related to premature battery depletion. FDA recommends that all eligible patients receive the firmware update at their next regularly scheduled visit or when appropriate, depending on the preferences of the patient and physician. Firmware is a type of software embedded in the hardware of a medical device.

Related News Articles

Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
Members of the pharmaceutical distribution supply chain, including dispensers such as hospitals and pharmacies, can apply through March 11 to participate in a…
Headline
The U.S. District Court for the Western District of Pennsylvania has entered a consent decree prohibiting Ranier’s Rx Laboratory Inc. from manufacturing or…
Headline
The Food and Drug Administration Friday warned physicians and patients who use medical devices to monitor levels of the blood thinner warfarin that certain…
Headline
The Healthcare and Public Health Sector Coordinating Council (HSCC) today released a consensus-based guide to developing, deploying and supporting cyber-secure…
Headline
The AHA today submitted to the Food and Drug Administration legislative, regulatory and best practice recommendations to address new and chronic prescription…